Cargando…

The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study

In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szabo, Agoston Gyula, Iversen, Katrine Fladeland, Möller, Sören, Plesner, Torben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Atlantis Press 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432372/ https://www.ncbi.nlm.nih.gov/pubmed/34595433 http://dx.doi.org/10.2991/chi.d.190805.002

Ejemplares similares

The Incidence and Timing of Blood Cultures in Multiple Myeloma – Results from a Retrospective, Single Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2020)

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
por: Szabo, Agoston Gyula, et al.
Publicado: (2023)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4(+) T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
por: Iversen, Katrine Fladeland, et al.
Publicado: (2022)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
por: Hiemstra, Ida H., et al.
Publicado: (2023)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59
por: Brennan, Kieran, et al.
Publicado: (2022)

Does Ethnicity Matter in Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents? Evidence From Real-World Data
por: Farswan, Akanksha, et al.
Publicado: (2021)

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
por: Brechbühl, Simon, et al.
Publicado: (2021)

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
por: Teramachi, Jumpei, et al.
Publicado: (2023)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
por: Katodritou, Eirini, et al.
Publicado: (2018)

Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
por: Zhao, Qian, et al.
Publicado: (2019)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Real-World Clinical Outcomes in Elderly Chinese Patients with Multiple Myeloma: A Single-Center Experience
por: Qian, Xifeng, et al.
Publicado: (2018)

Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland
por: Loponen, Heidi, et al.
Publicado: (2023)

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT.
por: Brioli, Annamaria, et al.
Publicado: (2023)

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017)

Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
por: Martino, Massimo, et al.
Publicado: (2020)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study
por: Nasr, Fadi, et al.
Publicado: (2021)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*
por: Lund, Thomas, et al.
Publicado: (2010)

Is There an Optimal Timing of Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Agents?
por: Toprak, Selami Koçak
Publicado: (2013)

Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China
por: Ding, Kai, et al.
Publicado: (2020)

P859: PROGNOSTIC IMPACT OF OPIOID USE PRIOR TO DIAGNOSIS OF MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore
por: Bayani, Diana Beatriz, et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center
por: Bondili, Suresh Kumar, et al.
Publicado: (2021)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eceisorvs2ce370ivs9okncs80